This Reading Room is a collaboration between MedPage Today® and:
Adding carboplatin to adjuvant chemotherapy with epirubicin plus cyclophosphamide followed by taxanes (EC-T) significantly improved outcomes in patients with early-stage triple-negative breast cancer (TNBC), according to a phase III trial in the Journal of Clinical Oncology.
Kunwei Shen, MD, of the Shanghai Jiao Tong University School of Medicine in China, and colleagues randomized 786 patients to have either adjuvant EC-T or EC-T plus carboplatin (EC-TCb). At a median follow-up of 4.5 years, patients who received carboplatin had significantly improved disease-free survival (HR 0.66, P=0.034), distant disease-free survival (HR 0.61, P=0.040), and overall survival (HR 0.39, P=0.029).
"Together, these findings highlight that carboplatin in combination with a standard EC-T regimen can be considered in the adjuvant setting for patients with early-stage TNBC who were treated first with primary surgery," the researchers concluded.
They were not available for further comment, and the responses below are taken from the paper.
